Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, ...

AbbVie, Danaher, Organovo, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of ...

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel ...